Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
35,033
archived clinical trials in
Lung Cancer

Erlotinib and Standard Platinum-Based Chemotherapy for Newly Diagnosed, Advanced Non-Small Cell Carcinoma of the Lung
INST 0601C: A Non-Randomized Phase II Protocol of Erlotinib for Patients With Newly Diagnosed, Advanced Non-Small Cell Carcinoma of the Lung
Status: Enrolling
Updated:  8/14/2015
Presbyterian Medical Group
mi
from
Albuquerque, NM
Erlotinib and Standard Platinum-Based Chemotherapy for Newly Diagnosed, Advanced Non-Small Cell Carcinoma of the Lung
INST 0601C: A Non-Randomized Phase II Protocol of Erlotinib for Patients With Newly Diagnosed, Advanced Non-Small Cell Carcinoma of the Lung
Status: Enrolling
Updated: 8/14/2015
Presbyterian Medical Group
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Erlotinib and Standard Platinum-Based Chemotherapy for Newly Diagnosed, Advanced Non-Small Cell Carcinoma of the Lung
INST 0601C: A Non-Randomized Phase II Protocol of Erlotinib for Patients With Newly Diagnosed, Advanced Non-Small Cell Carcinoma of the Lung
Status: Enrolling
Updated:  8/14/2015
University of New Mexico Cancer Center
mi
from
Albuquerque, NM
Erlotinib and Standard Platinum-Based Chemotherapy for Newly Diagnosed, Advanced Non-Small Cell Carcinoma of the Lung
INST 0601C: A Non-Randomized Phase II Protocol of Erlotinib for Patients With Newly Diagnosed, Advanced Non-Small Cell Carcinoma of the Lung
Status: Enrolling
Updated: 8/14/2015
University of New Mexico Cancer Center
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Erlotinib and Standard Platinum-Based Chemotherapy for Newly Diagnosed, Advanced Non-Small Cell Carcinoma of the Lung
INST 0601C: A Non-Randomized Phase II Protocol of Erlotinib for Patients With Newly Diagnosed, Advanced Non-Small Cell Carcinoma of the Lung
Status: Enrolling
Updated:  8/14/2015
New Mexico Cancer Care Associates
mi
from
Santa Fe, NM
Erlotinib and Standard Platinum-Based Chemotherapy for Newly Diagnosed, Advanced Non-Small Cell Carcinoma of the Lung
INST 0601C: A Non-Randomized Phase II Protocol of Erlotinib for Patients With Newly Diagnosed, Advanced Non-Small Cell Carcinoma of the Lung
Status: Enrolling
Updated: 8/14/2015
New Mexico Cancer Care Associates
mi
from
Santa Fe, NM
Click here to add this to my saved trials
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study
Status: Enrolling
Updated:  8/17/2015
Clinical Research Facility
mi
from
Corona, CA
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study
Status: Enrolling
Updated: 8/17/2015
Clinical Research Facility
mi
from
Corona, CA
Click here to add this to my saved trials
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study
Status: Enrolling
Updated:  8/17/2015
Clinical Research Facility
mi
from
Fountain Valley, CA
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study
Status: Enrolling
Updated: 8/17/2015
Clinical Research Facility
mi
from
Fountain Valley, CA
Click here to add this to my saved trials
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study
Status: Enrolling
Updated:  8/17/2015
Clinical Research Facility
mi
from
Fullerton, CA
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study
Status: Enrolling
Updated: 8/17/2015
Clinical Research Facility
mi
from
Fullerton, CA
Click here to add this to my saved trials
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study
Status: Enrolling
Updated:  8/17/2015
Clinical Research Facility
mi
from
Glendale, CA
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study
Status: Enrolling
Updated: 8/17/2015
Clinical Research Facility
mi
from
Glendale, CA
Click here to add this to my saved trials
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study
Status: Enrolling
Updated:  8/17/2015
Clinical Research Facility
mi
from
La Jolla, CA
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study
Status: Enrolling
Updated: 8/17/2015
Clinical Research Facility
mi
from
La Jolla, CA
Click here to add this to my saved trials
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study
Status: Enrolling
Updated:  8/17/2015
Clinical Research Facility
mi
from
Riverside, CA
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study
Status: Enrolling
Updated: 8/17/2015
Clinical Research Facility
mi
from
Riverside, CA
Click here to add this to my saved trials
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study
Status: Enrolling
Updated:  8/17/2015
Clinical Research Facility
mi
from
Washington,
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study
Status: Enrolling
Updated: 8/17/2015
Clinical Research Facility
mi
from
Washington,
Click here to add this to my saved trials
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study
Status: Enrolling
Updated:  8/17/2015
Clinical Research Facility
mi
from
Orange City, FL
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study
Status: Enrolling
Updated: 8/17/2015
Clinical Research Facility
mi
from
Orange City, FL
Click here to add this to my saved trials
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study
Status: Enrolling
Updated:  8/17/2015
Clinical Research Facility
mi
from
Quincy, IL
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study
Status: Enrolling
Updated: 8/17/2015
Clinical Research Facility
mi
from
Quincy, IL
Click here to add this to my saved trials
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study
Status: Enrolling
Updated:  8/17/2015
Clinical Research Facility
mi
from
Indianapolis, IN
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study
Status: Enrolling
Updated: 8/17/2015
Clinical Research Facility
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study
Status: Enrolling
Updated:  8/17/2015
Clinical Research Facility
mi
from
Louisville, KY
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study
Status: Enrolling
Updated: 8/17/2015
Clinical Research Facility
mi
from
Louisville, KY
Click here to add this to my saved trials
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study
Status: Enrolling
Updated:  8/17/2015
Clinical Research Facility
mi
from
Boston, MA
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study
Status: Enrolling
Updated: 8/17/2015
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study
Status: Enrolling
Updated:  8/17/2015
Clinical Research Facility
mi
from
Lake Success, NY
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study
Status: Enrolling
Updated: 8/17/2015
Clinical Research Facility
mi
from
Lake Success, NY
Click here to add this to my saved trials
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study
Status: Enrolling
Updated:  8/17/2015
Clinical Research Facility
mi
from
Durham, NC
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study
Status: Enrolling
Updated: 8/17/2015
Clinical Research Facility
mi
from
Durham, NC
Click here to add this to my saved trials
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study
Status: Enrolling
Updated:  8/17/2015
Clinical Research Facility
mi
from
Cleveland, OH
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study
Status: Enrolling
Updated: 8/17/2015
Clinical Research Facility
mi
from
Cleveland, OH
Click here to add this to my saved trials
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study
Status: Enrolling
Updated:  8/17/2015
Clinical Research Facility
mi
from
Sylvania, OH
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study
Status: Enrolling
Updated: 8/17/2015
Clinical Research Facility
mi
from
Sylvania, OH
Click here to add this to my saved trials
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study
Status: Enrolling
Updated:  8/17/2015
Clinical Research Facility
mi
from
West Reading, PA
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study
Status: Enrolling
Updated: 8/17/2015
Clinical Research Facility
mi
from
West Reading, PA
Click here to add this to my saved trials
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study
Status: Enrolling
Updated:  8/17/2015
Clinical Research Facility
mi
from
Charleston, SC
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study
Status: Enrolling
Updated: 8/17/2015
Clinical Research Facility
mi
from
Charleston, SC
Click here to add this to my saved trials
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study
Status: Enrolling
Updated:  8/17/2015
Clinical Research Facility
mi
from
Falls Church, VA
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study
Status: Enrolling
Updated: 8/17/2015
Clinical Research Facility
mi
from
Falls Church, VA
Click here to add this to my saved trials
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study
Status: Enrolling
Updated:  8/17/2015
mi
from
Prairiewood,
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study
Status: Enrolling
Updated: 8/17/2015
mi
from
Prairiewood,
Click here to add this to my saved trials
Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer
A Phase II Study of Concurrent Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer: Hoosier Oncology Group LUN08-129
Status: Enrolling
Updated:  8/17/2015
Northwestern University Feinberg School of Medicine
mi
from
Chicago, IL
Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer
A Phase II Study of Concurrent Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer: Hoosier Oncology Group LUN08-129
Status: Enrolling
Updated: 8/17/2015
Northwestern University Feinberg School of Medicine
mi
from
Chicago, IL
Click here to add this to my saved trials
Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer
A Phase II Study of Concurrent Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer: Hoosier Oncology Group LUN08-129
Status: Enrolling
Updated:  8/17/2015
Northshore University Health System, Kellogg Cancer Center
mi
from
Evanston, IL
Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer
A Phase II Study of Concurrent Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer: Hoosier Oncology Group LUN08-129
Status: Enrolling
Updated: 8/17/2015
Northshore University Health System, Kellogg Cancer Center
mi
from
Evanston, IL
Click here to add this to my saved trials
Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer
A Phase II Study of Concurrent Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer: Hoosier Oncology Group LUN08-129
Status: Enrolling
Updated:  8/17/2015
Medical and Surgical Specialists, LLC
mi
from
Galesburg, IL
Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer
A Phase II Study of Concurrent Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer: Hoosier Oncology Group LUN08-129
Status: Enrolling
Updated: 8/17/2015
Medical and Surgical Specialists, LLC
mi
from
Galesburg, IL
Click here to add this to my saved trials
Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer
A Phase II Study of Concurrent Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer: Hoosier Oncology Group LUN08-129
Status: Enrolling
Updated:  8/17/2015
Cancer Care Center of Southern Indiana
mi
from
Bloomington, IN
Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer
A Phase II Study of Concurrent Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer: Hoosier Oncology Group LUN08-129
Status: Enrolling
Updated: 8/17/2015
Cancer Care Center of Southern Indiana
mi
from
Bloomington, IN
Click here to add this to my saved trials
Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer
A Phase II Study of Concurrent Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer: Hoosier Oncology Group LUN08-129
Status: Enrolling
Updated:  8/17/2015
Fort Wayne Oncology & Hematology, Inc
mi
from
Fort Wayne, IN
Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer
A Phase II Study of Concurrent Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer: Hoosier Oncology Group LUN08-129
Status: Enrolling
Updated: 8/17/2015
Fort Wayne Oncology & Hematology, Inc
mi
from
Fort Wayne, IN
Click here to add this to my saved trials
Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer
A Phase II Study of Concurrent Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer: Hoosier Oncology Group LUN08-129
Status: Enrolling
Updated:  8/17/2015
IN Onc/Hem Associates
mi
from
Indianapolis, IN
Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer
A Phase II Study of Concurrent Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer: Hoosier Oncology Group LUN08-129
Status: Enrolling
Updated: 8/17/2015
IN Onc/Hem Associates
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer
A Phase II Study of Concurrent Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer: Hoosier Oncology Group LUN08-129
Status: Enrolling
Updated:  8/17/2015
Indiana University Simon Cancer Center
mi
from
Indianapolis, IN
Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer
A Phase II Study of Concurrent Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer: Hoosier Oncology Group LUN08-129
Status: Enrolling
Updated: 8/17/2015
Indiana University Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer
A Phase II Study of Concurrent Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer: Hoosier Oncology Group LUN08-129
Status: Enrolling
Updated:  8/17/2015
Community Regional Cancer Center
mi
from
Indianapolis, IN
Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer
A Phase II Study of Concurrent Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer: Hoosier Oncology Group LUN08-129
Status: Enrolling
Updated: 8/17/2015
Community Regional Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer
A Phase II Study of Concurrent Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer: Hoosier Oncology Group LUN08-129
Status: Enrolling
Updated:  8/17/2015
Horizon Oncology Center
mi
from
Lafayette, IN
Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer
A Phase II Study of Concurrent Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer: Hoosier Oncology Group LUN08-129
Status: Enrolling
Updated: 8/17/2015
Horizon Oncology Center
mi
from
Lafayette, IN
Click here to add this to my saved trials
Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer
A Phase II Study of Concurrent Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer: Hoosier Oncology Group LUN08-129
Status: Enrolling
Updated:  8/17/2015
Medical Consultants, P.C.
mi
from
Muncie, IN
Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer
A Phase II Study of Concurrent Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer: Hoosier Oncology Group LUN08-129
Status: Enrolling
Updated: 8/17/2015
Medical Consultants, P.C.
mi
from
Muncie, IN
Click here to add this to my saved trials
Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer
A Phase II Study of Concurrent Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer: Hoosier Oncology Group LUN08-129
Status: Enrolling
Updated:  8/17/2015
Monroe Medical Associates
mi
from
Munster, IN
Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer
A Phase II Study of Concurrent Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer: Hoosier Oncology Group LUN08-129
Status: Enrolling
Updated: 8/17/2015
Monroe Medical Associates
mi
from
Munster, IN
Click here to add this to my saved trials
Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer
A Phase II Study of Concurrent Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer: Hoosier Oncology Group LUN08-129
Status: Enrolling
Updated:  8/17/2015
Northern Indiana Cancer Research Consortium
mi
from
South Bend, IN
Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer
A Phase II Study of Concurrent Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer: Hoosier Oncology Group LUN08-129
Status: Enrolling
Updated: 8/17/2015
Northern Indiana Cancer Research Consortium
mi
from
South Bend, IN
Click here to add this to my saved trials
Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer
A Phase II Study of Concurrent Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer: Hoosier Oncology Group LUN08-129
Status: Enrolling
Updated:  8/17/2015
Providence Medical Group
mi
from
Terre Haute, IN
Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer
A Phase II Study of Concurrent Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer: Hoosier Oncology Group LUN08-129
Status: Enrolling
Updated: 8/17/2015
Providence Medical Group
mi
from
Terre Haute, IN
Click here to add this to my saved trials
Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer
A Phase II Study of Concurrent Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer: Hoosier Oncology Group LUN08-129
Status: Enrolling
Updated:  8/17/2015
Siteman Cancer Center
mi
from
St. Louis, MO
Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer
A Phase II Study of Concurrent Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer: Hoosier Oncology Group LUN08-129
Status: Enrolling
Updated: 8/17/2015
Siteman Cancer Center
mi
from
St. Louis, MO
Click here to add this to my saved trials
Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer
A Phase II Study of Concurrent Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer: Hoosier Oncology Group LUN08-129
Status: Enrolling
Updated:  8/17/2015
Hematology Oncology Associates S.J., P.A.
mi
from
Mt. Holly, NJ
Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer
A Phase II Study of Concurrent Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer: Hoosier Oncology Group LUN08-129
Status: Enrolling
Updated: 8/17/2015
Hematology Oncology Associates S.J., P.A.
mi
from
Mt. Holly, NJ
Click here to add this to my saved trials
Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer
A Phase II Study of Concurrent Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer: Hoosier Oncology Group LUN08-129
Status: Enrolling
Updated:  8/17/2015
Providence Portland Medical Center
mi
from
Portland, OR
Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer
A Phase II Study of Concurrent Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer: Hoosier Oncology Group LUN08-129
Status: Enrolling
Updated: 8/17/2015
Providence Portland Medical Center
mi
from
Portland, OR
Click here to add this to my saved trials
Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer
A Phase II Study of Concurrent Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer: Hoosier Oncology Group LUN08-129
Status: Enrolling
Updated:  8/17/2015
Pennsylvania Oncology Hematology Associates
mi
from
Philadelphia, PA
Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer
A Phase II Study of Concurrent Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer: Hoosier Oncology Group LUN08-129
Status: Enrolling
Updated: 8/17/2015
Pennsylvania Oncology Hematology Associates
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer
A Phase II Study of Concurrent Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer: Hoosier Oncology Group LUN08-129
Status: Enrolling
Updated:  8/17/2015
Fox Chase Cancer Center Extramural Research Program
mi
from
Rockledge, PA
Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer
A Phase II Study of Concurrent Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer: Hoosier Oncology Group LUN08-129
Status: Enrolling
Updated: 8/17/2015
Fox Chase Cancer Center Extramural Research Program
mi
from
Rockledge, PA
Click here to add this to my saved trials
Resistance Training in Lung Cancer Patients on Chemotherapy
Effectiveness of a Resistance Training Program on Inflammatory Markers and Chemotherapy Completion in Lung Cancer Patients on Chemotherapy
Status: Enrolling
Updated:  8/19/2015
Leo Jenkins Cancer Center
mi
from
Greenville, NC
Resistance Training in Lung Cancer Patients on Chemotherapy
Effectiveness of a Resistance Training Program on Inflammatory Markers and Chemotherapy Completion in Lung Cancer Patients on Chemotherapy
Status: Enrolling
Updated: 8/19/2015
Leo Jenkins Cancer Center
mi
from
Greenville, NC
Click here to add this to my saved trials
Safety Study of XL647 and XL147 Administered in Combination Daily in Adults With Solid Tumors
A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL647 and XL147 Administered in Combination Daily to Subjects With Solid Tumors
Status: Enrolling
Updated:  8/19/2015
Memorial Sloan-Kettering Cancer Center
mi
from
New York City, NY
Safety Study of XL647 and XL147 Administered in Combination Daily in Adults With Solid Tumors
A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL647 and XL147 Administered in Combination Daily to Subjects With Solid Tumors
Status: Enrolling
Updated: 8/19/2015
Memorial Sloan-Kettering Cancer Center
mi
from
New York City, NY
Click here to add this to my saved trials
Safety Study of XL647 and XL147 Administered in Combination Daily in Adults With Solid Tumors
A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL647 and XL147 Administered in Combination Daily to Subjects With Solid Tumors
Status: Enrolling
Updated:  8/19/2015
South Texas Accelerated Research Therapeutics
mi
from
San Antonio, TX
Safety Study of XL647 and XL147 Administered in Combination Daily in Adults With Solid Tumors
A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL647 and XL147 Administered in Combination Daily to Subjects With Solid Tumors
Status: Enrolling
Updated: 8/19/2015
South Texas Accelerated Research Therapeutics
mi
from
San Antonio, TX
Click here to add this to my saved trials
Bupropion in Helping Adults Stop Smoking
A Phase II Study of the Effects of Extended Pre-Cessation Bupropion for Smoking Cessation
Status: Enrolling
Updated:  8/27/2015
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Bupropion in Helping Adults Stop Smoking
A Phase II Study of the Effects of Extended Pre-Cessation Bupropion for Smoking Cessation
Status: Enrolling
Updated: 8/27/2015
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Cognitive Testing of Tobacco Use Measurement Items for Administration With Cancer Patients and Survivors
Cognitive Testing of Tobacco Use Measurement Items for Administration With Cancer Patients and Survivors
Status: Enrolling
Updated:  8/28/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Cognitive Testing of Tobacco Use Measurement Items for Administration With Cancer Patients and Survivors
Cognitive Testing of Tobacco Use Measurement Items for Administration With Cancer Patients and Survivors
Status: Enrolling
Updated: 8/28/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Trial of BIBW 2992 (Afatinib) + Cetuximab in Non-Small Cell Lung Cancer
A Phase Ib Open-label Clinical Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 Plus Cetuximab (Erbitux®) in Patients With Non-small Cell Lung Cancer With Progression Following Prior Erlotinib (Tarceva®) or Gefitinib (Iressa®)
Status: Enrolling
Updated:  8/29/2015
1199.14.1190 Boehringer Ingelheim Investigational Site
mi
from
Aurora, CO
Trial of BIBW 2992 (Afatinib) + Cetuximab in Non-Small Cell Lung Cancer
A Phase Ib Open-label Clinical Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 Plus Cetuximab (Erbitux®) in Patients With Non-small Cell Lung Cancer With Progression Following Prior Erlotinib (Tarceva®) or Gefitinib (Iressa®)
Status: Enrolling
Updated: 8/29/2015
1199.14.1190 Boehringer Ingelheim Investigational Site
mi
from
Aurora, CO
Click here to add this to my saved trials
Trial of BIBW 2992 (Afatinib) + Cetuximab in Non-Small Cell Lung Cancer
A Phase Ib Open-label Clinical Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 Plus Cetuximab (Erbitux®) in Patients With Non-small Cell Lung Cancer With Progression Following Prior Erlotinib (Tarceva®) or Gefitinib (Iressa®)
Status: Enrolling
Updated:  8/29/2015
1199.15.10028 Boehringer Ingelheim Investigational Site
mi
from
New Haven, CT
Trial of BIBW 2992 (Afatinib) + Cetuximab in Non-Small Cell Lung Cancer
A Phase Ib Open-label Clinical Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 Plus Cetuximab (Erbitux®) in Patients With Non-small Cell Lung Cancer With Progression Following Prior Erlotinib (Tarceva®) or Gefitinib (Iressa®)
Status: Enrolling
Updated: 8/29/2015
1199.15.10028 Boehringer Ingelheim Investigational Site
mi
from
New Haven, CT
Click here to add this to my saved trials
Trial of BIBW 2992 (Afatinib) + Cetuximab in Non-Small Cell Lung Cancer
A Phase Ib Open-label Clinical Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 Plus Cetuximab (Erbitux®) in Patients With Non-small Cell Lung Cancer With Progression Following Prior Erlotinib (Tarceva®) or Gefitinib (Iressa®)
Status: Enrolling
Updated:  8/29/2015
Boehringer Ingelheim Investigational Site
mi
from
New York, NY
Trial of BIBW 2992 (Afatinib) + Cetuximab in Non-Small Cell Lung Cancer
A Phase Ib Open-label Clinical Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 Plus Cetuximab (Erbitux®) in Patients With Non-small Cell Lung Cancer With Progression Following Prior Erlotinib (Tarceva®) or Gefitinib (Iressa®)
Status: Enrolling
Updated: 8/29/2015
Boehringer Ingelheim Investigational Site
mi
from
New York, NY
Click here to add this to my saved trials
Trial of BIBW 2992 (Afatinib) + Cetuximab in Non-Small Cell Lung Cancer
A Phase Ib Open-label Clinical Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 Plus Cetuximab (Erbitux®) in Patients With Non-small Cell Lung Cancer With Progression Following Prior Erlotinib (Tarceva®) or Gefitinib (Iressa®)
Status: Enrolling
Updated:  8/29/2015
1200.71.1002 Boehringer Ingelheim Investigational Site
mi
from
Nashville, TN
Trial of BIBW 2992 (Afatinib) + Cetuximab in Non-Small Cell Lung Cancer
A Phase Ib Open-label Clinical Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 Plus Cetuximab (Erbitux®) in Patients With Non-small Cell Lung Cancer With Progression Following Prior Erlotinib (Tarceva®) or Gefitinib (Iressa®)
Status: Enrolling
Updated: 8/29/2015
1200.71.1002 Boehringer Ingelheim Investigational Site
mi
from
Nashville, TN
Click here to add this to my saved trials